ImmunityBio, Inc. Common Stock (IBRX)

Price$6.92

Value ScoreF

Growth ScoreA

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)185.30%

Price vs S&P 500 (4W)-18.67%

VGM Score56.08

Market Capitalization$7.25B

All Metrics

Book Value / Share (Quarterly)$1.37

P/TBV (Annual)3.09x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)678.62%

Cash Flow / Share (Quarterly)$-0.30

Price vs S&P 500 (YTD)241.34%

Gross Margin (TTM)99.34%

Net Profit Margin (TTM)-606.15%

EPS (TTM)$-0.85

10-Day Avg Trading Volume14.63M

EPS Excl Extra (TTM)$-0.85

Revenue Growth (5Y)184.30%

EPS (Annual)$-0.38

ROI (Annual)-129.86%

Gross Margin (Annual)99.34%

Net Profit Margin (5Y Avg)-61547.29%

Cash / Share (Quarterly)$0.38

Revenue Growth QoQ (YoY)167.64%

ROA (Last FY)-70.01%

Revenue Growth TTM (YoY)351.53%

EBITD / Share (TTM)$-0.27

ROE (5Y Avg)-69.68%

Operating Margin (TTM)-185.41%

Cash Flow / Share (Annual)$-0.31

P/B Ratio48.77x

P/B Ratio (Quarterly)5.04x

Net Income / Employee (Annual)$-508,500

EV / Revenue (TTM)57.64x

Net Interest Coverage (TTM)-1.40x

ROA (TTM)-165.16%

EPS Incl Extra (Annual)$-0.38

Current Ratio (Annual)5.10x

Quick Ratio (Quarterly)6.24x

3-Month Avg Trading Volume23.21M

52-Week Price Return138.62%

Revenue / Employee (TTM)$204,000

Tangible BV / Share (Quarterly)$1.23

P/S Ratio (Annual)63.98x

Asset Turnover (Annual)0.23x

52-Week High$12.43

Operating Margin (5Y Avg)-48537.75%

EPS Excl Extra (Annual)$-0.38

CapEx CAGR (5Y)20.55%

26-Week Price Return193.22%

Quick Ratio (Annual)4.62x

13-Week Price Return-22.77%

Total Debt / Equity (Annual)0.01x

Current Ratio (Quarterly)6.67x

Enterprise Value$8.13B

Revenue / Share Growth (5Y)138.40%

Asset Turnover (TTM)0.27x

Revenue / Employee (Annual)$163,900

Pretax Margin (Annual)-310.37%

Cash / Share (Annual)$0.24

3-Month Return Std Dev92.34%

Net Income / Employee (TTM)$-1,236,700

ROE (Last FY)-130.72%

Net Interest Coverage (Annual)-1.48x

EPS Basic Excl Extra (Annual)$-0.38

Receivables Turnover (TTM)4.68x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.85

Receivables Turnover (Annual)5.04x

ROI (TTM)-193.00%

P/S Ratio (TTM)51.41x

Pretax Margin (5Y Avg)-61695.41%

Revenue / Share (Annual)$0.12

Tangible BV / Share (Annual)$1.23

Price vs S&P 500 (52W)114.26%

Year-to-Date Return249.49%

5-Day Price Return-4.42%

EPS Normalized (Annual)$-0.38

ROA (5Y Avg)-96.51%

Net Profit Margin (Annual)-310.18%

Month-to-Date Return-7.98%

Cash Flow / Share (TTM)$-1.09

EBITD / Share (Annual)$-0.26

Operating Margin (Annual)-226.00%

ROI (5Y Avg)-68.78%

EPS Basic Excl Extra (TTM)$-0.85

P/TBV (Quarterly)3.09x

P/B Ratio (Annual)3.09x

Inventory Turnover (TTM)0.21x

Pretax Margin (TTM)-606.12%

Book Value / Share (Annual)$1.23

Price vs S&P 500 (13W)-31.02%

Beta0.19x

Revenue / Share (TTM)$0.14

ROE (TTM)-193.29%

52-Week Low$1.95

vGradeF

gGradeA

mGradeB

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.08est. -0.07

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.27

Industry Peers — Biological Products(178)

Symbol	Value Score	Growth Score	Momentum Score	Price
IBRXImmunityBio, Inc. Common Stock	F	A	B	$6.92
AMGNAmgen Inc	C	C	C	$349.58
GILDGilead Sciences Inc	C	B	C	$129.16
ARGXargenx SE American Depositary Shares	D	A	B	$891.32
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$149.23
BIIBBiogen Inc. Common Stock	B	D	B	$195.34
BNTXBioNTech SE American Depositary Share	C	C	D	$88.08
MRNAModerna, Inc. Common Stock	C	B	B	$47.44
NBIXNeurocrine Biosciences Inc	C	B	B	$163.88
EXELExelixis Inc	C	B	B	$52.70
KRYSKrystal Biotech, Inc. Common Stock	D	B	A	$301.00

About

ImmunityBio develops immunotherapies for cancer and infectious diseases through its proprietary Cancer BioShield platform, which activates both adaptive and innate immune systems. The platform is anchored by ANKTIVA, an IL-15 superagonist, complemented by adenovirus-vectored vaccines and NK-cell therapies. The company generates the majority of its revenue in the United States, with additional operations in Europe.